Loading stock…

Innovent Biologics, Inc. (1801) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Innovent Biologics, Inc.

1801Market cap $22BPrice $12.0

Country🇨🇳China

SectorHealthcare

IndustryBiotechnology

Develops and manufactures biologic drugs, including cancer and autoimmune treatments, for China's massive patient population. Its blockbuster PD-1 inhibitor rivals Western competitors' pricing but sells at a fraction of the cost.

In Bastion Portfolios?

52W Return+7%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+41%10

Revenue Forecast

Rev CAGR (1y)+49%10

Rev CAGR (3y)+29%10

Rev CAGR (5y)+24%10

Earnings Forecast

EPS Growth Y+1+190%10

EPS Growth Y+2+57%9

EPS Growth Y+3+21%8

Quality

Margins

EBIT Margin7%4

Net Income Margin8%5

Free Cash Flow Margin82%10

Debt

Net Debt/EBITDA-9.710

Efficiency

ROE7%3

ROA4%5

Earnings Stability44

GEAR+STRONG78

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)511

P/E Ratio (Forward 3y)311

P/BV7.02

EV Multiples

EV/EBITDA Fwd421

EV/EBIT Fwd511

Yield

Free Cash Flow Yield8.9%9

Dividend Yieldna–

Momentum

Short term

1 month return-3%6

3 month return+13%9

YTD return+28%8

Mid term

Price vs 52wHigh83%6

1 year return-7%4

Long term

3 year return+150%9

5 year return+28%5

Risk Shield

Price Risk

Beta0.76

Volatility47%3

Free Cash Flow

Free Cash Flow Margin82%10

Free Cash Flow Yield8.9%9

Quality

ROCE5%3

Earnings Stability44

Net Debt/EBITDA-9.710

02Growth

Is it actually growing, and how fast?

1801Innovent Biologics

Revenue FY25$1.9B

GROWTH RATING↗

VERY STRONG99 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+41%10

Revenue, next 1Y+49%10

Revenue, next 3Y, CAGR+29%10

Revenue, next 5Y, CAGR+24%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+190%10

EPS growth, FY27E+57%9

EPS growth, FY28E+21%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 99% of companies worldwide.

Revenue grew 41%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 29%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 24%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 57%/yr vs revenue 29%/yr), so margins should widen.

WATCH

Revenue grew 41%/yr over the last 3 years; forecasts see it cooling to 29%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

1801Innovent Biologics

Total return Current288%

Price return Current288%

MOMENTUM RATING↗

STRONG67 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+13%9

YTD return+28%8

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return-7%4

3-year return+150%9

5-year return+28%5

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +150% over three years and +28% over five, ahead of 60% of the market.

Strong recent results. The stock is outperforming over three months (+13%) and so far this year (+28%).

WATCH

It's down 7% over the past year, now 17% below its 52-week high. That is right in line with the market.

Returns sit at the market level over the past month (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Innovent Biologics. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

1801Innovent Biologics

Revenue FY25$1.9B

GROWTH RATING↗

VERY STRONG99 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+41%10

Revenue, next 1Y+49%10

Revenue, next 3Y, CAGR+29%10

Revenue, next 5Y, CAGR+24%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+190%10

EPS growth, FY27E+57%9

EPS growth, FY28E+21%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 99% of companies worldwide.

Revenue grew 41%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 29%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 24%/yr over five years.10/10

Earnings are set to grow faster than sales (EPS about 57%/yr vs revenue 29%/yr), so margins should widen.

WATCH

Revenue grew 41%/yr over the last 3 years; forecasts see it cooling to 29%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

1801Innovent Biologics

Total return Current288%

Price return Current288%

MOMENTUM RATING↗

STRONG67 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+13%9

YTD return+28%8

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return-7%4

3-year return+150%9

5-year return+28%5

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +150% over three years and +28% over five, ahead of 60% of the market.

Strong recent results. The stock is outperforming over three months (+13%) and so far this year (+28%).

WATCH

It's down 7% over the past year, now 17% below its 52-week high. That is right in line with the market.

Returns sit at the market level over the past month (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Innovent Biologics. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community